Syra Health Corp.
SYRA
$0.3488
-$0.0102-2.84%
| Weiss Ratings | SYRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | SYRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | SYRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | SYRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -8.48% | |||
| 30-Day Total Return | -30.27% | |||
| 60-Day Total Return | -16.25% | |||
| 90-Day Total Return | -16.95% | |||
| Year to Date Total Return | -20.67% | |||
| 1-Year Total Return | -79.84% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -84.19% | |||
| 52-Week Low % Change | 11.84% | |||
| Price | SYRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.27 | |||
| 52-Week Low Price | $0.32 | |||
| 52-Week Low Price (Date) | Mar 12, 2025 | |||
| 52-Week High Price (Date) | May 08, 2024 | |||
| Valuation | SYRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 6.21M | |||
| Enterprise Value | 4.27M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.65 | |||
| Earnings Per Share Growth | 14.73% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.34 | |||
| Price/Book (Q) | 1.87 | |||
| Enterprise Value/Revenue (TTM) | 0.55 | |||
| Price | $0.35 | |||
| Enterprise Value/EBITDA (TTM) | -1.02 | |||
| Enterprise Value/EBIT | -1.00 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | SYRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 7.26M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SYRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 463 345 8950 | |||
| Address | 1119 Keystone Way North Carmel, IN 46032 | |||
| Website | www.syrahealth.com | |||
| Country | United States | |||
| Year Founded | 2020 | |||
| Profitability | SYRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -54.89% | |||
| Profit Margin | -54.90% | |||
| Management Effectiveness | SYRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -75.54% | |||
| Return on Equity | -- | |||
| Income Statement | SYRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 7.74M | |||
| Total Revenue (TTM) | 7.74M | |||
| Revenue Per Share | $1.07 | |||
| Gross Profit (TTM) | 1.78M | |||
| EBITDA (TTM) | -4.18M | |||
| EBIT (TTM) | -4.25M | |||
| Net Income (TTM) | -4.25M | |||
| Net Income Avl. to Common (TTM) | -4.25M | |||
| Total Revenue Growth (Q YOY) | 42.50% | |||
| Earnings Growth (Q YOY) | -17.80% | |||
| EPS Diluted (TTM) | -0.65 | |||
| EPS Diluted Growth (Q YOY) | 29.27% | |||
| Balance Sheet | SYRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.70M | |||
| Cash Per Share (Q) | $0.37 | |||
| Total Current Assets (Q) | 4.06M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 3.33M | |||
| Current Ratio (Q) | 4.631 | |||
| Book Value Per Share (Q) | $0.19 | |||
| Total Assets (Q) | 4.43M | |||
| Total Current Liabilities (Q) | 877.80K | |||
| Total Debt (Q) | 565.70K | |||
| Total Liabilities (Q) | 1.09M | |||
| Total Common Equity (Q) | 3.33M | |||
| Cash Flow | SYRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -11.10K | |||
| Cash from Financing (TTM) | 7.16M | |||
| Net Change in Cash (TTM) | 2.68M | |||
| Levered Free Cash Flow (TTM) | -3.51M | |||
| Cash from Operations (TTM) | -4.47M | |||
